loncastuximab tesirine + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone

A **multi-agent combination regimen** consisting of loncastuximab tesirine (an anti-CD19 antibody-drug conjugate), rituximab (an anti-CD20 monoclonal antibody), cyclophosphamide (an alkylating agent), doxorubicin (an anthracycline antibiotic and topoisomerase II inhibitor), vincristine (a vinca alkaloid that inhibits microtubule formation), and prednisone (a synthetic glucocorticoid). This combination is being investigated mainly in **relapsed/refractory aggressive B-cell lymphomas** (including double-hit and double-expressor lymphomas and follicular lymphoma). Each component has a distinct mechanism of action targeting B-cell malignancy via immune-mediated, cytotoxic, and cell cycle effects. This regimen adds targeted antibody-drug conjugate therapy to standard immunochemotherapy.